Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
31.45
-0.21 (-0.66%)
At close: Oct 10, 2025, 4:00 PM EDT
31.49
+0.04 (0.13%)
After-hours: Oct 10, 2025, 7:32 PM EDT
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,294 employees as of December 31, 2024. The number of employees increased by 18 or 1.41% compared to the previous year.
Employees
1,294
Change (1Y)
18
Growth (1Y)
1.41%
Revenue / Employee
$471,529
Profits / Employee
-$411,849
Market Cap
3.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | 893 | 153 | 20.68% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RARE News
- 8 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - GlobeNewsWire
- 19 days ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 5 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Ultragenyx to Participate at Investor Conferences in September - GlobeNewsWire
- 7 weeks ago - Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire